|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Notably, multivariate analysis identified advanced T stage and low miR-126 level as independent predictors of the unfavorable prognosis and recurrence of LN-negative GC.
|
30248047 |
2018 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To assess the utility of the combination of serum miR-126 and multi-detector computed tomography (MDCT) in predicting LNM preoperatively in GC.
|
29843221 |
2018 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results indicate for the first time that serum miR-126 may serve as a novel prognostic biomarker in GC.
|
29562500 |
2018 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results indicate for the first time that miR-126 down-regulation and Crk protein up-regulation may be synergistically associated with tumor progression in GC and may predict unfavorable prognosis of GC.
|
29171987 |
2018 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The expression of miR-126 suggests GC recurrence and metastasis, which shed crucial light on how miR-126 functions in GC pathogenesis.
|
29510776 |
2018 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, as directly targeted by miR-126 in GC, ADAM9 may be a potential target for GC therapeutic treatment which warrants intensive study.
|
28260063 |
2017 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interestingly, our pathways analysis and the follow-up dual-luciferase reporter assay showed that there is a direct 3'-untranslated region binding site between RGS3 mRNA and microRNA-126, a GC inhibitor.
|
27754994 |
2017 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genetic silencing of EZH2 mirrored the effects of miR-126 in drug resistance, and restoration of EZH2 blocked the inhibitory effect of miR-126 on GC.
|
27622325 |
2016 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MicroRNA-126 regulates migration and invasion of gastric cancer by targeting CADM1.
|
26464628 |
2015 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, our results suggests and consolidates the standpoint that miR-126 plays a pivotal role in GC suppressing the process of GC cell, and this function is at least partly taken to implement by miR-126s's post-transcriptional effect on LAT-1.
|
26054677 |
2015 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Crystal violet test and Transwell assay were conducted to explore the effects of miR-126 on the proliferation and invasion of human GC cell lines, respectively.
|
25027343 |
2014 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overall, the results from our study suggested that miR-126 could suppress tumor growth and tumor angiogenesis of GC through VEGF-A signaling, and it is a novel potential therapeutic target for GC.
|
25428912 |
2014 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, the targeting relationship between CRKL and miR-126 partly reveals the mechanism of miR-126 on GC suppression.
|
24055140 |
2013 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, our results suggest that miR-126 may function as a tumour suppressor in gastric cancer, with Crk as a direct target.
|
20619534 |
2010 |